MedPlus Subsidiary Faces 7-Day Drug License Suspension in Andhra Pradesh

Medplus Health Services has reported a regulatory setback for its subsidiary, Optival Health Solutions Private Limited. The company disclosed that Optival received a seven-day suspension order for a drug license at one of its stores in Andhra Pradesh.

Suspension Details

The suspension order, issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Rajamahendravaram, E.G District, affects a store located in Devi Chowk, Andhra Pradesh. The order was received on October 13, 2025, and cites Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 as the basis for the suspension.

Financial Impact

Medplus has estimated the potential financial impact of this suspension:

Impact Category	Amount
Estimated Revenue Loss	Rs. 1.75 lakhs

Regulatory Compliance

The company has promptly disclosed this information in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure aligns with recent SEBI circulars aimed at enhancing transparency in corporate communications.

Investor Information

Medplus has assured stakeholders that detailed information regarding this suspension will be available on the company's official website as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

While the immediate financial impact appears limited, this incident highlights the regulatory challenges faced by pharmaceutical retail chains in India.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.68%	+3.11%	+0.58%	-10.63%	-4.54%	-27.49%

Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received a 15-day suspension order for a drug license at one of its stores in Maharashtra.

Suspension Details

The Assistant Commissioner & Licensing Authority of Food & Drug Administration, Nagpur, issued the suspension order for a store located in Vishwakarma Nagar, Nagpur. The order cites a violation under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus Health Services estimates a potential revenue loss of approximately Rs. 2.29 lakhs due to this suspension. The company disclosed this information in compliance with SEBI regulations, specifically Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The suspension order aligns with recent SEBI circulars, which require listed entities to disclose such regulatory actions promptly.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, confirmed that the details of the suspension order will be available on the company's website as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

This incident highlights the ongoing regulatory scrutiny in the pharmaceutical retail sector and the importance of maintaining compliance with drug licensing regulations.